Sarcoma, Soft Tissue Clinical Trial
Official title:
A Phase II Study Evaluating Efficacy of the Combination of Gemcitabine and Vinorelbine in Advanced Soft Tissue Sarcoma
The purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.
Patients will receive both gemcitabine and vinorelbine once a week for two weeks and then
one week with no chemotherapy (1 cycle equals 21 days). Gemcitabine and vinorelbine will be
administered on day 1 and day 8 of each cycle.
Blood tests will be performed on each day chemotherapy is administered. A CT scan will be
done after every 2 cycles (approximately every 6 weeks) to determine the effects of the
chemotherapy on the sarcoma.
A physical exam will be performed at the start of chemotherapy and at least every three
weeks thereafter.
Patients will remain on this study as long as the disease does not progress or there are no
unacceptable side effects.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03985722 -
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
|
Phase 1 | |
| Withdrawn |
NCT02464332 -
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
|
Phase 1 | |
| Completed |
NCT00289809 -
TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01185964 -
A Study of IMC-3G3 in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00753688 -
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
|
Phase 3 | |
| Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT03798795 -
Radiomics for Tumor Grading of Soft Tissue Sarcomas.
|
||
| Terminated |
NCT02929394 -
Trabectedin Maintenance Post 1st-line in STS
|
Phase 3 | |
| Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00406601 -
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
|
Phase 2 | |
| Completed |
NCT00297258 -
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT06114173 -
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
|
Early Phase 1 | |
| Completed |
NCT00061659 -
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03815474 -
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Recruiting |
NCT02812654 -
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
|
Phase 2 | |
| Completed |
NCT00204620 -
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
|
Phase 2 | |
| Completed |
NCT03058406 -
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
|
||
| Active, not recruiting |
NCT02415816 -
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
|
N/A |